Evidence map›Paper›PMID 41373580›Full record

ArticleInternational journal of molecular sciences2025

Chronic Overexpression of Neuronal NRG1-III in Mice Causes Long-Term Detrimental Changes in Lower Motor Neurons, Neuromuscular Synapses and Motor Behaviour.

Sara Salvany, Sara Hernández, Anna Casanovas, Sílvia Gras, Lídia Piedrafita, Mar Bosch-Queralt, Markus H Schwab, Jordi Calderó, Josep E Esquerda, Olga Tarabal

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sara SalvanyGrup de Patologia Neuromuscular Experimental, Departament de Medicina Experimental, Facultat de Medicina, Universitat de Lleida, 25198 Lleida, Spain.ORCID 0000-0002-4250-6689
Sara HernándezGrup de Patologia Neuromuscular Experimental, Departament de Medicina Experimental, Facultat de Medicina, Universitat de Lleida, 25198 Lleida, Spain.ORCID 0000-0002-6451-724X
Anna CasanovasGrup de Patologia Neuromuscular Experimental, Departament de Medicina Experimental, Facultat de Medicina, Universitat de Lleida, 25198 Lleida, Spain.ORCID 0009-0004-8563-3460
Sílvia GrasGrup de Patologia Neuromuscular Experimental, Departament de Medicina Experimental, Facultat de Medicina, Universitat de Lleida, 25198 Lleida, Spain.ORCID 0000-0002-5172-379X
Lídia PiedrafitaGrup de Patologia Neuromuscular Experimental, Departament de Medicina Experimental, Facultat de Medicina, Universitat de Lleida, 25198 Lleida, Spain.ORCID 0000-0001-8151-7447
Mar Bosch-QueraltPaul-Flechsig Institute for Brain Research, Medical Faculty, University Leipzig, 04103 Leipzig, Germany.ORCID 0000-0002-5374-8755
Markus H SchwabPaul-Flechsig Institute for Brain Research, Medical Faculty, University Leipzig, 04103 Leipzig, Germany.ORCID 0000-0003-2477-2892
Jordi CalderóGrup de Patologia Neuromuscular Experimental, Departament de Medicina Experimental, Facultat de Medicina, Universitat de Lleida, 25198 Lleida, Spain.ORCID 0000-0003-1972-0115
Josep E EsquerdaGrup de Patologia Neuromuscular Experimental, Departament de Medicina Experimental, Facultat de Medicina, Universitat de Lleida, 25198 Lleida, Spain.ORCID 0000-0003-1413-2103
Olga TarabalGrup de Patologia Neuromuscular Experimental, Departament de Medicina Experimental, Facultat de Medicina, Universitat de Lleida, 25198 Lleida, Spain.ORCID 0000-0001-7741-3223

Funding

Marató de TV3 Foundation 202005-30Ministerio de Ciencia e Innovación PID2021-122785OB-I00
6 · The paper itself

Abstract

Neuregulins (NRGs) are ligands of tyrosine kinase receptors from the ErbB family and play multiple developmental roles. NRG1-ErbB signaling regulates myelination and has been associated with amyotrophic lateral sclerosis (ALS) pathology. Given the potential therapeutic relevance of this pathway for motor neuron (MN) diseases, we employed a transgenic (TG) mouse with persistent neuronal overexpression of neuregulin type III (NRG1-III) to investigate its impact on the neuromuscular system. We performed an analysis of phenotypic changes in this TG model, including motor behavior, neuropathological evaluation by immunocytochemistry and ultrastructural examination of the spinal cord, peripheral nerves, and neuromuscular junctions (NMJs). Calcium dynamics in cultured MNs were also examined. We found that cholinergic C-boutons on TG MNs, where NRG1-III typically accumulates, exhibited upregulation of C-bouton-associated proteins and expansion of the subsynaptic cistern (SSC)-associated endoplasmic reticulum. Calcium imaging revealed altered homeostasis in TG MNs, accompanied by the upregulation of molecules linked to axonal plasticity. At NMJs, regressive changes involving autophagic dysregulation were observed. These alterations were accompanied by increased motor activity in behavioral tests. Overall, our findings indicate that persistently elevated NRG1-III signaling compromises MN connectivity and long-term health, a factor to consider when developing therapeutic strategies for neurodegenerative diseases such as ALS.

Indexed as

Motor ActivityMotor NeuronsNeuregulin-1Neuromuscular JunctionAmyotrophic Lateral SclerosisAnimalsCalciumDisease Models, AnimalMiceMice, TransgenicSpinal CordCalciumNeuregulin-1Nrg1 protein, mousedegenerationmotor neuron (MN)muscleNeuregulin 1 (NRG1)neuromuscular junction (NMJ)plasticityspinal cordsynapse

Identifiers

PMID41373580
PMCPMC12692416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.